Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Ampion for COVID-19 Respiratory Distress
NCT04868890Phase 2Terminated
- Sponsor
- Ampio Pharmaceuticals, Inc.
- Start
- Jun 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of aspartyl-alanyl-diketopiperazine in coronavirus disease 2019 (COVID-19), sponsored by Ampio Pharmaceuticals, Inc.. Started Jun 2021; status: terminated.
02
Drugs
aspartyl-alanyl-diketopiperazine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04868890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04868890.